Apexigen, Inc.

Brookline Capital Acquisition Corp. (Nasdaq: BCAC), a blank-check company sponsored by Brookline Capital Markets, announced a definitive business combination agreement with Apexigen, Inc. on March 18, 2022. The SPAC completed its initial public offering in 2021 with a focus on the biotechnology and pharmaceutical sector. Apexigen, a clinical-stage biopharmaceutical company developing antibody-based oncology therapies, became the surviving public entity following the close of the transaction. The deal represents one of several life-sciences de-SPAC combinations announced during that period as sponsors pursued clinical-stage targets. To access complete filing histories, deal timelines, and analytical data on this and thousands of other SPAC transactions, sign up for full access at SpacDesk.

SPAC Counterparty (1)